No Data
Erkang Pharmaceuticals: Report for the third quarter of 2024
hunan er-kang pharmaceutical (300267.SZ): a net loss of 31.7675 million yuan in the third quarter.
On October 24, Gelonhui reported that Hunan Er-Kang Pharmaceutical (300267.SZ) achieved revenue of 0.233 billion yuan in the third quarter of 2024, a year-on-year decrease of 41.06%; net income attributable to shareholders of the listed company was -31.7675 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -34.3959 million yuan; basic earnings per share was -0.0154 yuan.
Concept Mining | A major breakthrough in the "longevity drug", will concept stocks usher in a period of outbreak?
Increase by 100 times.
A-share macrobiotic nmn concept stocks continue to rise, xiamen kingdomway group hits the limit up.
On October 24, Xiamen Kingdomway Group hit the daily limit, Aba Chemicals Corporation rose by more than 10%, Hunan Er-Kang Pharmaceutical, Guangdong Zhongsheng Pharmaceutical, Brother Enterprises Holding, dezhan healthcare and others led the gainers. On the news front, according to the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, the institute has achieved over a 100-fold increase in the production of nicotinamide mononucleotide (NMN) by developing a de novo synthesis pathway. Reports indicate that Tianjin Institute of Industrial Biotechnology successfully developed a de novo synthesis pathway for NMN in E. coli through systematic engineering, effectively increasing the in vivo metabolic production of NMN.
Express News | Hunan Er-Kang Pharmaceutical: Supervisor Li Haiyi resigned due to personal reasons.
hunan er-kang pharmaceutical (300267.SZ): The construction work of the first selected ore dressing plant investment in Nigeria has been basically completed.
Gelonghui October 11th | hunan er-kang pharmaceutical (300267.SZ) recently stated at the performance briefing that the company's first ore dressing plant investment in Nigeria has been basically completed, and the equipment debugging work is currently being accelerated to strive for early product delivery.
No Data
No Data